Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi [Seeking Alpha]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Seeking Alpha
Icotyde, the first oral IL-23 receptor antagonist for plaque psoriasis, offers best-in-class oral efficacy and placebo-like safety, with significant royalty and milestone potential. PTGX's pipeline, validated by Icotyde and Rusfertide, leverages its proprietary Vectrix platform to target obesity, hematology, and inflammation, supporting long-term value creation. Upcoming catalysts include Rusfertide's Q3 2026 PDUFA date and multiple Icotyde label expansion studies, positioning the company for durable profitability and potential acquisition interest. Kwangmoozaa/iStock via Getty Images Last Wednesday , Johnson & Johnson ( JNJ announced that the FDA had approved Icotyde, a once-daily oral peptide for the treatment of plaque psoriasis. This drug selectively blocks the interleukin-23 receptor (IL-23) and was a joint discovery with
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Golfweek Masters Survey: Favorite picture from Augusta National [USA TODAY]USA TODAY
- Johnson & Johnson (JNJ) Advances Bladder Cancer Treatment with 89% Response Rate [Yahoo! Finance]Yahoo! Finance
- ???????????????????? : ???????????????2035??3?3534?????? CAGR9%??????????????????????????? [CNET News]CNET News
- Protagonist Therapeutics Soars as FDA Approves ICOTYDE for Plaque Psoriasis, Triggers $50M Milestone [Yahoo! Finance]Yahoo! Finance
- Jim Cramer on Johnson & Johnson: “It's a Textbook Slowdown Stock” [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 3/18/26 - Form 13F-HR/A
- 3/18/26 - Form 13F-HR/A
- 3/12/26 - Form 4
- JNJ's page on the SEC website